For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240129:nRSc1347Ba&default-theme=true
RNS Number : 1347B RUA Life Sciences PLC 29 January 2024
29 January 2024
RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")
Directorate Change
RUA Life Sciences (AIM: RUA), the holding company of a group of medical
device businesses focused on the exploitation of the world's leading long-term
implantable biostable polymer (Elast-Eon™), announces that with immediate
effect Caroline Stretton, Group Managing Director, has resigned as a director
of the Company and is leaving her role as Group Managing Director to pursue
other business opportunities.
The executive directors will continue to manage the Company supported by the
non-executive directors. The Board is considering the appropriate longer
term management structure of the Company and further announcements will be
made in due course, as appropriate.
Bill Brown, Chairman of RUA, said: "The Board of RUA thanks Caroline for her
hard work over the last year and wishes her well for the future. RUA is
pursuing a number of opportunities to develop the business further and these
will play a part in the future shape of the senior leadership team. Current
trading remains in line with the Board's expectations."
For further information contact:
RUA Life Sciences
Bill Brown, Executive Chairman Tel: +44 (0)1294 317073
Lachlan Smith, Chief Financial Officer
Cavendish Capital Markets Tel: +44 (0)20 7220 0500
Limited
(Nominated Adviser and Broker)
Giles Balleny/Dan Hodkinson (Corporate Finance)
Charlie Combe (Broking)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA Life
Sciences Plc (formerly known as AorTech International Plc) acquired RUA
Medical Devices Limited to create a fully formed medical device
business. RUA Life Sciences is the holding company of the Group's four
trading businesses, each exploiting the Group's patented polymer technology.
Our vision is to improve the lives of millions of patients by enabling medical
devices with Elast-Eon(TM), the world's leading long-term implantable
polyurethane. Whether it is licensing Elast-Eon(TM), manufacturing a device or
component, or developing next generation medical devices, a RUA Life
Sciences business is pursuing our vision.
Elast-Eon™'s biostability is comparable to silicone while exhibiting
excellent mechanical, blood contacting and flex-fatigue properties. These
polymers can be processed using conventional thermoplastic extrusion and
moulding techniques. With over 8 million implants and 15 years of successful
clinical use, RUA's polymers are proven in long-term life enabling
applications.
The Group's four business units are:
RUA Contract Manufacture: End-to-end contract developer and manufacturer of medical devices and
implantable fabric specialist.
RUA Biomaterials: Licensor of Elast-Eon(TM) polymers to the medical device industry.
RUA Vascular: Commercialisation of open surgical vascular grafts and patches
RUA Structural Heart: Development of polymeric leaflet systems for heart valves.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOABVLLLZFLEBBZ